Maged A Ghali

Maged A Ghali, M.D.

Professor; Chief, Division Of Gastroenterology; Program Director, Gastroenterology Fellowship

Department: Medicine – Jacksonville
Business Phone: (904) 244-8846
Business Email: maged.ghali@jax.ufl.edu

About Maged A Ghali

Maged Ghali, M.D., is a University of Florida professor of medicine and a board-certified gastroenterologist and transplant hepatologist at UF Health Jacksonville. He also serves as chief of the UF Division of Gastroenterology in Jacksonville, as well as program director of the Gastroenterology Fellowship training program. Dr. Ghali received his medical degree from McGill University in Montreal, Canada. He completed his internal medicine residency and gastroenterology fellowship at McGill University Health Center-Royal Victoria Hospital. He also completed fellowship training in transplant hepatology at Mayo Clinic in Rochester, Minnesota.

Board Certifications

  • Gastroenterology
    American Board of Internal Medicine
  • Transplant Hepatology
    American Board of Internal Medicine

Clinical Profile

Specialties
  • Gastroenterology
  • Internal Medicine
  • Transplant Hepatology
Subspecialties
  • Gastroenterology
  • Transplant Hepatology

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0001-5914-3231

Publications

2024
Improved outcomes of kidney after liver transplantation after the implementation of the safety net policy
Liver Transplantation. 30(6):582-594 [DOI] 10.1097/lvt.0000000000000302.
2024
Kidney after liver transplantation does not have an increased risk of rejection compared to liver alone
Clinical Transplantation. 38(4) [DOI] 10.1111/ctr.15311.
2023
Acute haemorrhagic ischaemic colitis secondary to cocaine use.
BMJ case reports. 16(9) [DOI] 10.1136/bcr-2023-255704. [PMID] 37666567.
2023
Self-awareness of hepatitis C infection in the United States: A cross-sectional study based on the National Health Nutrition and Examination Survey
PLOS ONE. 18(10) [DOI] 10.1371/journal.pone.0293315. [PMID] 37874815.
2021
Esophageal Perforation after Using a Single-Use Disposable Duodenoscope.
Case reports in gastroenterology. 15(3):972-977 [DOI] 10.1159/000519685. [PMID] 35110984.
2020
Multiple myeloma with hepatic amyloid light-chain amyloidosis manifesting as progressive liver failure.
BMJ case reports. 13(6) [DOI] 10.1136/bcr-2020-234637. [PMID] 32601138.
2019
What Patients Want in a Smartphone App That Supports Colonoscopy Preparation: Qualitative Study to Inform a User-Centered Smartphone App
JMIR mHealth and uHealth. 7(7) [DOI] 10.2196/12242. [PMID] 31125310.
2017
Incidence and Predictors of Advanced Liver Fibrosis by a Validated Serum Biomarker in Liver Transplant Recipients
Canadian Journal of Gastroenterology and Hepatology. 2017:1-8 [DOI] 10.1155/2017/4381864. [PMID] 28409147.

Grants

Jan 2024 – Jun 2024
Re-linkage to Care in the United States
Role: Other
Funding: CENTER FOR DISEASE ANALYSIS FOUNDATION via GILEAD SCIENCES
Mar 2023 ACTIVE
A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)
Role: Principal Investigator
Funding: SYNEOS HEALTH via MADRIGAL PHARMACEUTICALS
Dec 2022 ACTIVE
An Open-Label Study to Evaluate the Safety and Tolerability of Volixibat in Patients with Primary Biliary Cholangitis Currently Being Treated with Obeticholic Acid
Role: Principal Investigator
Funding: SYNEOS HEALTH via MIRUM PHARMACEUTICALS
Apr 2022 ACTIVE
Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo controlled trial
Role: Principal Investigator
Funding: NOVO NORDISK
Mar 2022 ACTIVE
A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects with Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)
Role: Principal Investigator
Funding: GILEAD SCIENCES
Feb 2022 ACTIVE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (VANTAGE)
Role: Principal Investigator
Funding: SYNEOS HEALTH via MIRUM PHARMACEUTICALS
Feb 2021 ACTIVE
Biospecimen Resource for Hepatocellular Carcinoma Research
Role: Principal Investigator
Funding: MAYO CLINIC
Oct 2020 – Dec 2022
NFL/ Cancer Screening during COVID-19 Project 2020 – 2021
Role: Principal Investigator
Funding: AMERICAN CANCER SOCIETY
Sep 2020 ACTIVE
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate-to- Severe Crohn's Disease
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO via BRISTOL MYERS SQUIBB CO
Apr 2020 – Dec 2023
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES via BRISTOL MYERS SQUIBB CO
Mar 2020 ACTIVE
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH)
Role: Principal Investigator
Funding: EAST COAST INSTITUTE FOR RESEARCH via ELI LILLY AND CO
Mar 2020 ACTIVE
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects with Moderately to Severely Active Crohns Disease
Role: Principal Investigator
Funding: IQVIA LTD via ARENA PHARMACEUTICALS
Feb 2020 – Dec 2023
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
Role: Principal Investigator
Funding: DRUGDEV INC via ARENA PHARMACEUTICALS
Jan 2020 – Dec 2023
An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
Role: Principal Investigator
Funding: DRUGDEV INC via ARENA PHARMACEUTICALS
Nov 2019 ACTIVE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
Role: Principal Investigator
Funding: IQVIA LTD via ARENA PHARMACEUTICALS
Jul 2018 – Jun 2024
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis
Role: Principal Investigator
Funding: INTERCEPT PHARMACEUTICALS
Aug 2017 ACTIVE
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Role: Principal Investigator
Funding: TARGET PHARMASOLUTIONS dba TARGET RWE
May 2017 – Oct 2021
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
Role: Principal Investigator
Funding: GILEAD SCIENCES
Mar 2017 – Mar 2021
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy
Role: Project Manager
Funding: ABBVIE
Dec 2016 – Jun 2024
A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma
Role: Principal Investigator
Funding: TARGET PHARMASOLUTIONS dba TARGET RWE
Dec 2016 ACTIVE
A 5-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis
Role: Principal Investigator
Funding: TARGET PHARMASOLUTIONS dba TARGET RWE
Nov 2016 ACTIVE
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
Role: Principal Investigator
Funding: INTERCEPT PHARMACEUTICALS
Jan 2016 – Mar 2022
Prioritize Study
Role: Project Manager
Funding: PATIENT-CENTERED OUTCOMES RES INST
Oct 2011 ACTIVE
HCV-TARGET Primary Operating Project with subprojects
Role: Project Manager
Funding: UF DIV OF SPONSORED RESEARCH

Education

Transplant Hepatology Fellowship
2005 · Mayo Clinic
Gastroenterology Fellowship
2004 · McGill University Health Center – Royal Victoria Hospital
Internal Medicine Residency
2001 · McGill University Health Center – Royal Victoria Hospital
Doctor of Medicine
1998 · McGill University

Contact Details

Phones:
Business:
(904) 244-8846
Emails:
Addresses:
Business Mailing:
653 W 8TH ST
JACKSONVILLE FL 32209
Business Street:
653-1 W 8TH ST
108 BENT PINE CT
JACKSONVILLE FL 322096511